Prostate Cell News Volume 6.37 | Oct 2 2015

LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer
Scientists report HOTAIR as an androgen-repressed lncRNA, and, as such, it is markedly upregulated following androgen deprivation therapies and in castration-resistant prostate cancer. [Cell Rep]
Full Article | Graphical Abstract

Targeting of Cytosolic Phospholipase A2α Impedes Cell Cycle Re-Entry of Quiescent Prostate Cancer Cells
Investigators determined the role of cytosolic phospholipase A2α (cPLA2α) in cell cycle re-entry of quiescent prostate cancer cells. When PC-3 and LNCaP cells were rendered to a quiescent state, the active form of cPLA2α with a phosphorylation at Ser505 was lower compared to their proliferating state. [Oncotarget] Full Article

Application of Mitochondrial Pyruvate Carrier Blocker UK5099 Creates Metabolic Reprogram and Greater Stem-Like Properties in LnCap Prostate Cancer Cells In Vitro
Researchers investigated the relationship between blocking mitochondrial pyruvate carrier with UK5099 and the metabolic alteration as well as stemness phenotype of prostatic cancer cells. [Oncotarget] Full Article

AMBRA1 and SQSTM1 Expression Pattern in Prostate Cancer
The authors demonstrated an increased expression of AMBRA1 and the autophagic protein sequestosome-1 (SQSTM1), which were also associated with an accumulation of LC3II in prostate cancer but not in benign lesion. [Apoptosis] Full Article

Transmembrane Prostatic Acid Phosphatase (TMPAP) Delays Cells in G1 Phase of the Cell Cycle
Researchers report that the stable overexpression of transmembrane prostatic acid phosphatase (TMPAP), but not the secreted isoform in LNCaP cells reduces cell growth while increasing endo/exocytosis and cell size. Specifically, cells overexpressing TMPAP accumulate in the G1 phase of the cell cycle, and show altered gene expression profile. [Prostate] Abstract

Analysis of TMEFF2 Allografts and Transgenic Mouse Models Reveals Roles in Prostate Regeneration and Cancer
Previous results indicated a tumor suppressor role for the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) in prostate cancer. Here, scientists further characterized this role and uncovered new functions for TMEFF2 in cancer and adult prostate regeneration. [Prostate] Abstract

Osteopontin Splice Variants Expression Is Involved on Docetaxel Resistance in PC3 Prostate Cancer Cells
Researchers investigated some cellular mechanisms by which osteopontin splice variants could mediate PC3 prostate cancer cell survival and growth in response to docetaxel-induced cell death. [Tumor Biol] Abstract

Brassinin Combined with Capsaicin Enhances Apoptotic and Anti-Metastatic Effects in PC-3 Human Prostate Cancer Cells
Researchers analyzed the potential synergistic anti-tumor effects of brassinin combined with capsaicin on prostate cancer PC-3 cells. [Phytother Res] Abstract

CLINICAL RESEARCH

OLIGOPELVIS – GETUG P07: A Multicenter Phase II Trial of Combined Salvage Radiotherapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
Investigators assessed the two year outcome in oligometastatic prostate cancer patients treated concomitantly with high-dose intensity-modulated radiation therapy and androgen-deprivation therapy for six months. [BMC Cancer] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

From our sponsor: Induce neural progenitor cells faster and more effectively. Watch the technical video.

Canadian Researchers Pioneer Next-Generation Therapy for Prostate Cancer
A team of scientists and clinicians is developing a treatment for prostate cancer using viruses that destroy cancer cells and boost the anti-cancer immune response, yet leave normal cells unharmed. The team has received $5 million from Prostate Cancer Canada and the Movember Foundation. [McMaster University] Press Release

Governor Cuomo Announces $3 Million in Funding for Prostate Cancer Research
Governor Andrew Cuomo announced $3 million in prostate cancer research funding has been awarded to 20 research institutions across the state to explore new and innovative concepts in prostate cancer detection, diagnosis and treatment. [New York State] Press Release

NDSU Researchers to Use $1.2 Million Grant to Combat Prostate Cancer
Two NDSU researchers have received one of the National Institutes of Health’s most competitive grants to study a new way of combating prostate cancer. [North Dakota State University] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Staff Scientist – Prostate Cancer Modeling (Fred Hutchinson Cancer Research Center)

Research Scientist – Epithelial Stem Cells (A*STAR)

Postdoctoral Fellow – Prostate Cancer Research (Rutgers Cancer Institute of New Jersey)

Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Positions – Stem Cell, Development and Cancer Biology (Columbia University Medical Center)

Staff Scientist – Cancer Modeling (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Drug Discovery and Action (University of Illinois)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.